Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension

Clinical and Developmental Immunology

Volumn 12, Issue 4, 2005, Pages 275-279

  Marasini, Bianca ^a,e   Cossutta, Roberta ^a   Selmi, Carlo ^a,b   Pozzi, Maria Rosa ^c   Gardinali, Marco ^c   Massarotti, Marco ^a   Erario, Maddalena ^d   Battaglioli, Lodovica ^d   Biondi, Maria Luisa ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN GERARDO HOSPITAL   (Italy)

^d SAN PAOLO HOSPITAL   (Italy)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Fractalkine; Genetics; Pulmonary hypertension; Scleroderma

Indexed keywords

CHEMOKINE RECEPTOR; FRACTALKINE; FRACTALKINE RECEPTOR CX3CR1; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOPPLER ECHOCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS;

CHEMOKINE CX3CL1; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PULMONARY ARTERY; RECEPTORS, CHEMOKINE; SCLERODERMA, SYSTEMIC;

EID: 30344472950     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1080/17402520500303297     Document Type: Article

References (36)

1. Ancuta P, Rao R, et al. 2003. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 197:1701-1707.
2. Atamas SP, White B. 2003. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 15:772-777.
3. Badesch DB, Abman SH, et al. 2004. Medical therapy for pulmonary hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):35S-62S.
4. Balabanian K, Foussat A, et al. 2002. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165:1419-1425.
5. Bazan JF, Bacon KB, et al. 1997. A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640-644.
6. Brundage BH. 1990. Pulmonary hypertension in collagen vascular disease. In: Fishman A, editor. The pulmonary circulation. Philadelphia: University of Pennsylvania. p 353-358.
7. Cool CD, Kennedy D, et al. 1997. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28:434-442.
8. Daoudi M, Lavergne E, et al. 2004. Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1. J Biol Chem 279:19649-19657.
9. Dorfmuller P, Zarka V, et al. 2002. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 165:534-539.
10. Faller DV. 1999. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 26:74-84.
11. Faure S, Meyer L, et al. 2000. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287:2274-2277.
12. Fong AM, Robinson LA, et al. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188:1413-1419.
13. Fujii H, Shimada Y, et al. 2004. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 35:43-51.
14. Ghilardi G, Biondi ML, et al. 2004. Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: A genetic risk factor. Stroke 35:1276-1279.
15. Gugl A, Renner W, et al. 2003. Two polymorphisms in the fracalkine receptor CX3CR1 are not associated with peripheral arterial disease. Atherosclerosis 166:339-343.
16. Hasegawa M, Sato S, et al. 2005. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 64:21-28.
17. Hattori H, Ito D, et al. 2005. T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. Neurosci Lett 374:132-135.
18. Hussein MR, Hassan HI, et al. 2005. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 58:178-184.
19. Koch AE. 2000. The role of angiogenesis in rheumatoid arthritis: Recent developments. Ann Rheum Dis 59(Suppl. 1):i65-i71.
20. Koh ET, Lee P, et al. 1996. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol 35:989-993.
21. Kraling BM, Maul GG, et al. 1995. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 63:48-56.
22. Lavergne E, Labreuche J, et al. 2005. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol 25:847-853.
23. LeRoy EC. 1996. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22:675-694.
24. MacGregor AJ, Canavan R, et al. 2001. Pulmonary hypertension in systemic sclerosis: Risk factors for progression and consequences for survival. Rheumatology (Oxf.) 40:453-459.
25. McDermott DH, Halcox JP, et al. 2001. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 89:401-407.
26. McLaughlin VV, Presberg KW, et al. 2004. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126:78S-92S.
27. Moatti D, Faure S, et al. 2001. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97:1925-1928.
28. Preliminary criteria for the classification of systemic sclerosis (scleroderma) 1980. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581-590.
29. Prescott RJ, Freemont AJ, et al. 1992. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255-263.
30. Rudnicka L, Majewski S, et al. 1992. Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum 35:771-775.
31. Schachna L, Wigley FM, et al. 2003. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 124:2098-2104.
32. Steen V. 2003. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 62:97-99.
33. Tuder RM, Groves B, et al. 1994. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275-285.
34. Umehara H, Bloom ET, et al. 2004. Fractalkine in vascular biology: From basic research to clinical disease. Arterioscler Thromb Vasc Biol 24:34-40.
35. Volin MV, Woods JM, et al. 2001. Fractalkine: A novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 159:1521-1530.
36. Yamashita K, Imaizumi T, et al. 2003. Effect of hypoxia on the expression of fractalkine in human endothelial cells. Tohoku J Exp Med 200:187-194.